

References

- **Abelev GI (1971):** Alpha-Fetoprotein in association with malignant tumors. *Advances in Cancer Research*; 14: 295-357.
- **Afdhal NH, Dieterich DT, Pockros PJ, Schiff ER, Shiffman ML, Sulkowski MS, Wright T, Younossi Z, Goon BL, Tang KL and Bowers PJ (2004):** Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. *Gastroenterology*; 126(5):1302-11.
- **Ahmed M. Awadallah, Hesham Ali Issa and Mohamed S. Soliman (2011):** Evaluation of Serum Chromogranin A as a useful Tumor Marker for Diagnosis of Hepatocellular Carcinoma. *Journal of American Science*; 7(1):999-1007.
- **Aitken C (2002):** Markers and risk factors for HCV, HBV and HIV in a network of injecting drug users in Melbourne, Australia. *J Infect*; 58, 375-382.
- **Alcamí A, Symons JA and Smith GL (December 2000):** The vaccinia virus soluble alpha/beta interferon (IFN) receptor binds to the cell surface and protects cells from the antiviral effects of IFN. *J. Virol*; 74 (23): 11230–9.
- **Alexander P (1972):** Fetal antigens in cancer. *Nature*; 235:137–140.
- **Almasio PL, Venezia G and Craxì A (2003):** The impact of antiviral therapy on the course of chronic HCV infection. A systematic review. *Panminerva Med*; 45(3):175-82.

- **Alter HJ, Purcell RH, Shih JW et al (1989):** Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. *N Engl J Med*; 321(22):1494.
- **Alter MJ, Margolis HS, Krawczynski K, Judson FN, Mares A, Alexander WJ et al (1992):** The natural history of community-acquired hepatitis C in the United States. *N Engl J Med* 1992; 327:1899-905.
- **Alterman N, Fattal-Valevski A, Moyal L, Crawford TO, Lederman HM, Ziv Y and Shiloh Y (2007):** Ataxia-telangiectasia: mild neurological presentation despite null ATM mutation and severe cellular phenotype. *Am J Med Genet A*; 143A:1827–34.
- **American Association for the Study of Liver Diseases (2004):** Diagnosis, management, and treatment of hepatitis C. *Hepatology*; 39: 1147-1171.
- **American College of Obstetricians and Gynecologists (2007):** Screening for fetal chromosomal abnormalities. *ACOG Practice Bulletin No. 77. Obstetrics and Gynecology*; 109(1): 217–227.
- **Andreone P, Zignego AL, Cursaro C, Gramenzi A, Gherlinzoni F, Fiorino S, Giannini C, Boni P, Sabattini E, Pileri S, Tura S and Bernardi M (Aug 1998):** Prevalence of monoclonal gammopathies in patients with hepatitis C virus infection. *Ann Intern Med.* 15; 129(4):294-8.
- **Anonymous (2001):** Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HBV, HCV, and

- HIV and Recommendations for Postexposure Prophylaxis. MMWR Recomm Rep; 50(RR-11):1.
- **Antonelli A, Ferri C, Fallahi P, Pampana A, Ferrari SM, Goglia F and Ferrannini E (2005):** Hepatitis C virus infection: evidence for an association with type 2 diabetes. Diabetes Care; 28:2548-2550.
 - **Armstrong GL, Wasley A, Simard EP et al (2006):** The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Annals of Internal Medicine; 144:705–714.
 - **Arrieta O, Rodríguez-Díaz J, Rosas-Camargo V, Morales-Espinosa D, Ponce de León S, Kershenobich D and León-Rodríguez E (2006):** Colchicine delays the development of hepatocellular carcinoma in patients with hepatitis virus related-liver cirrhosis. Cancer; 107(8):1852-1858.
 - **Arthur RR, Hassan NF, Abdallah MY et al (1997):** Hepatitis C antibody prevalence in blood donors in different governorates in Egypt. Trans R Soc Trop Med Hyg; 91:271-4.
 - **Askarieh G, Alsiö A, Pugnale P et al (May 2010):** "Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C". Hepatology; 51 (5):1523–30.
 - **Atemezem A et al (2002):** Human alpha-fetoprotein binds to primary macrophages. Biochemical Biophysical Research Communications; 296(3): 507-514.
 - **Aussel C and Fehlmann M (1986):** Alpha-fetoprotein stimulates leukotriene synthesis in P388D1 macrophages. Cellular Immunology 101(2): 415-424.

- **Awad T, Thorlund K, Hauser G, Stimac D, Mabrouk M, Gluud C (April 2010):** Peginterferon Alpha-2a is associated with higher sustained virological response than peginterferon Alfa-2b in chronic hepatitis C: systematic review of randomized trials. *Hepatology* 51 (4): 1176–84.

- **B. Ramos; M. Núñez; A. Rendón; M. A. Berdún; E. Losada; I. Santos; S. Echevarría; A. Ocampo; C. Miralles; P. Arazo; P. Barreiro; M. Romero; P. Labarga; J. M. Guardiola; J. Garcia-Samaniego; V. Soriano(2005):** Critical Role of Ribavirin for the Achievement of Early Virological Response to HCV Therapy in HCV/HIV-Coinfected Patients. Posted: 07/05/2007; *J Viral Hepat.* 2007; 14(6):387-391.

- **Bacon BR (2002):** Patients with normal ALT levels. Report to NIH Consensus Development Conference, Management of hepatitis C. June 10-12, 2002.

- **Bader D, Riskin A, Vafsi O et al (2004):** Alpha-fetoprotein in the early neonatal period--a large study and review of the literature. *Clin. Chim. Acta*; 349 (1-2): 15–23.

- **Badizadegan K, Jonas MM, Ott MJ, Nelson SP, Perez-Atayde AR (November 1998):** Histopathology of the liver in children with chronic hepatitis C viral infection. *Hepatology*; p. 1416-1423, Vol. 28, No. 5.

- **Baggio VL, Pugliese RPS, Miura IK, Bassit L, Kempf AB, Gayotto LCC, Porta G (2000):** Treatment of Chronic Hepatitis C with Recombinant Interferon- α 2b in Childhood. *Journal of Pediatric Gastroenterology and Nutrition*. Volume 31, Supplement 2.

- **Baker, RD, Dee, D, Baker SS (2007):** Response to Pegylated Interferon a: 2b and Ribavirin in Children with Chronic Hepatitis C. *Journal of Clinical Gastroenterology*: 41:1:111-114.

- **Bani-Sadr, Firouzé, Lapidus, Nathanael, Rosenthal, Eric, Gerard, Laurence, Foltzer, Adeline, Perronne, Christian, Cacoub, Patrice, Pol, Stanislas, carrat, Fabrice (2005):** Gamma Glutamyl Transferase Elevation in HIV/Hepatitis C Virus-Coinfected Patients During Interferon-Ribavirin Combination Therapy *JAIDS Journal of Acquired Immune Deficiency Syndromes*; Volume 50 - Issue 4 - pp 429-430.

- **Barbaro G, Di Lorenzo G, Asti A et al (1999):** Hepatocellular mitochondrial alterations in patients with chronic hepatitis C: ultrastructural and biochemical findings. *Am J Gastroenterol*; 94(8):2198- 205.

- **Bayati, N, Silverman, AL and Gordon (1998):** SC. Serum alpha-fetoprotein levels and liver histology in patients with chronic hepatitis C. *Am. J. Gastroenterol*; 93: 2452-2456.

- **Beborowica J (1988):** Microheterogeneity of human alpha-fetoprotein. *Tumor Biology*; 9: 3-14.

- **Bedossa P, Poynard T and French METAVIR Cooperative Study Group (1996):** An algorithm for the grading of activity in chronic hepatitis C. *Hepatology*; 24:289-93.

- **Bennett JA et al (1997):** Similarity between natural and recombinant human AFP as inhibitors of estrogen-dependent breast cancer growth. *Breast Cancer Research and Treatment*; 45: 169-179.

- **Bennett JA et al (1998):** AFP derived from a human hepatoma prevents growth of estrogen-dependent human breast cancer xenografts. *Clinical Cancer Research*; 4: 2877-2884.
- **Berg T, von Wagner M, Nasser S, et al (2006):** Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa 2a plus ribavirin. *Gastroenterol*; 130:1086-1097.
- **Bertoletti A and Ferrari C (2003):** Kinetics of the immune response during HBV and HCV infection. *Hepatology*; 38:4-13.
- **Bhatti Z and Berenson CS (2007):** Adult systemic cat scratch disease associated with therapy for hepatitis C. *BMC Infect Dis* 7: 8.
- **Biswas RM, Nedjar S, Wilson LT et al (1994):** The effect on the safety of intravenous immunoglobulin of testing plasma for antibody to hepatitis C. *Trans fusion*; 34:100-104.
- **Booth JC, Foster GR, Kumar U, Galassini R, Goldin RD, Brown JL, Thomas HC Academic Department of Medicine, St Mary's Hospital Medical School, Imperial College of Science, Technology and Medicine, London. Hepatology Research** (Volume 37, Issue 7, pages 490–497. *Gut* x; 36930:427-32 Article Number: UI95212969.
- **Boyer JL (2001):** Liver Cirrhosis And Its Development: Proceedings Of The Falk Symposium 115. Springer. Pp. 344.
- **Breborowicz, J., Mackiewicz, A and Breborowicz, D.Scund. J. Zmmunol (1981):** Primary structures of human alpha-fetoprotein and its mRNA. p14, 15-20.

- **Brian I Carr, Petr Pancoska and Robert A Branch (2010):** Low alpha-fetoprotein hepatocellular carcinoma. *Hepatology* jgh_6303 1543-1549.
- **Brock DJ, Bolton AE, Monaghan JM (1973):** Prenatal diagnosis through maternal serum AFP measurement. *Lancet*; 2:293–294.
- **Brock DJH and Sutcliffe RG (1972):** Alpha-fetoprotein in the antenatal diagnosis of anencephaly and spina bifida. *Lancet*; 2: 197-194.
- **Bruix J and Sherman M (2005):** Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. *Hepatology*; 42:1208-1236.
- **Bruno S, Silini E, Crosignani A, Borzio F, Leandro G, Bono F, Asti M, Rossi S, Larghi A, Cerino A, Podda M, Mondelli MU (1997):** Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: A prospective study. *Hepatology*; 25:754.
- **Campbell JV, Hagan H, Latka MH, Et Al. (February 2006):** "High prevalence of alcohol use among hepatitis C virus antibody positive injection drug users in three US cities". *Drug and alcohol dependence*; 81 (3): 259–65.
- **Cann A.J (1997):** Principles of Molecular Virology. 2nd Edition, Academic Press: New York; 122-123.
- **Caruntu FA, Benea L (September 2006):** "Acute Hepatitis C Virus Infection: Diagnosis, Pathogenesis, Treatment". *Journal of Gastrointestinal and Liver Diseases* 15 (3): 249–56. PMID 17013450.

- **Castillo I, Pardo M, Bartolomé J, Ortiz-Movilla N, Rodríguez-Iñigo E, de Lucas S, Salas C, Jiménez-Heffernan JA, Pérez-Mota A, Graus J, López-Alcorocho JM, Carreño V (2004):** Occult hepatitis C virus infection in patients in whom the etiology of persistently abnormal results of liver-function tests is unknown. *J Infect Dis*; 1:189(1):7-14.
- **Castillo I, Rodríguez-Iñigo E, López-Alcorocho JM, Pardo M, Bartolomé J, Carreño V (November 2006):** "Hepatitis C Virus Replicates In The Liver Of Patients Who Have A Sustained Response To Antiviral Treatment". *Clinical Infectious Diseases*; 43 (10): 1277–83.
- **Centers for Disease Control and Prevention (CDC) (2001):** Recommendations for preventing transmission of infections among chronic hemodialysis patients. *MMWR*; 50 (RR-5): 28-29.
- **Chan, T.M., S.K. Ho, C.L. Lai, I.K. Cheng and K.N. Lai (1999):** Lymphocyte subsets in renal allograft recipients with chronic hepatitis C virus infection. *Nephrol. Dial. Transplant*, 14: 717-722.
- **Cheema AW, Hirschtritt T, Van Thiel DH (2004):** Markedly elevated alpha-fetoprotein levels without hepatocellular carcinoma. *Hepatogastroenterology*; 51(60): 1676–1678.
- **Chen H et al (1997):** Regulation and activities of alpha-fetoprotein. *Critical Reviews in Eukaryotic Gene Expression* 7 (1-2): 11-41.
- **Chen TM, Huang PT, Tsai MH, Lin LF, Liu CC, Ho KS, Siau CP, Chao PL, Tung JN (May 2007):** Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular

carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy. *J Gastroenterol Hepatol*; 22(5):669-75.

- **Chiu, W., Burnett, R.M., and Garcea, R (1997):** Structural Biology of Viruses. Oxford University Press: New York; 11, 22-25.
- **Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, and Houghton M (April 1989):** "Isolation Of A C DNA Clone Derived From A Blood-Borne Non-A, Non-B Viral Hepatitis Genome". *Science*; 244 (4902): 359–62.
- **Christina Frank, Mostafa K Mohamed, G Thomas Strickland, Daniel Lavanchy, Ray R Arthur, Laurence S Magder, Taha El Khoby, Yehia Abdel-Wahab, El Said Aly Ohn, Wagida Anwar, Ismail Sallam. (2000):** The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. *Lancet* 2000; 355: 887–891.
- **Comanor L, Elkin C, Leung K, Krajden M, Kronquist K, Nicolas K, Horansky E, kittichai P, Sablon E, Ziermann R, Sherlock C (2003):**Successful HCV genotyping of previously failed and low viral load specimen using an HCV RNA qualitative assay based on transcription-mediated amplification in conjunction with the line probe assay. *J Clin Virology*; 28:14-26.
- **Conjeevaram H.S., Fried M.W., Jeffers L.J., Terrault N.A., Wiley-Lucas T.E and Afdhal N (2006):** Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. *Gastroenterology*; 131:470–477.v

- **Cox AL, Netski DM, Mosbruger T et al (April 2005):** "Prospective evaluation of community-acquired acute-phase hepatitis C virus infection". *Clinical Infectious Diseases*; 40 (7): 951–8.
- **Crainie M et al (1989):** Regulation of constitutive and lymphokine-induced Ia expression by murine alpha-fetoprotein. *Cellular Immunology*; 118(1): 41-52.
- **Crandall BF (1981):** Alpha-fetoprotein; A review. *Critical Reviews in Clinical Laboratory Science*; 15: 127-185.
- **Czokalo M and Tomasiak M (1989):** Alpha fetoprotein inhibits aggregation of human platelets. *Haematologia (Budapest)*; 22(1): 11-18.
- **D. I. Johnston, A. P. Mowat, Hilary Orr and J. Kohn (1976):** Serum Alpha-fetoprotein levels in extra hepatic biliary. Article first published online: 21 JAN 2008. DOI: 10.1111/j.1651-2227.1976.tb04942.x
- **Danbi Lee, Young-Hwa Chung, Sae Hwan Lee, Yoon-Seon Lee, Don Lee, Jeong Eun Hwang, Kang Mo Kim, Young Suk Lim, Han Chu Lee, Eunsil Yu, Young Sang Lee and Dong Jin Suh (2007):** Biochemical rather than virologic response to interferon therapy may be Mmore closely associated with decrease of hepatocellular carcinoma Incidence in Patients with chronic Hepatitis C. *Gut and Liver*; Vol. 1, No. 1, pp. 49-55.
- **Daniel W (1998):** Bradley V. Chiron Corporation, 136 F. 3d 1317 (U.S. Court Of Appeals for the Federal Circuit).

- **Daniele B, Bencivenga A, Megna AS and Tinessa V (2004):** Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma. *Gastroenterology*; 127: 108-12.
- **Davis GL, Wong JB, McHutchison JG et al (2003):** Early virologic response to treatment with peginterferon alfa 2b plus ribavirin in patients with chronic hepatitis C. *Hepatology*; 38:645-652.
- **De Francesco R and Migliaccio G (2005):** Challenges and successes in developing new therapies for hepatitis C. *Nature*; 436:953–960.
- **Deutsch HF (1991):** Chemistry and biology of alpha-fetoprotein. *Advances in Cancer Research* 56: 253-312.
- **Di Bisceglie AM, Shiffman ML, Everson GT et al (2009):** Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. *New England Journal of Medicine*; 359:2429–2441.
- **Dudich E et al (2006):** Alpha-fetoprotein antagonizes X-linked inhibitor of apoptosis protein anticaspase activity and disrupts XIAP-cascade interaction. *FEBS Journal*; 273(16): 3837-3849.
- **Dudich EI et al (1999):** Alpha-fetoprotein causes apoptosis in tumor cells via activation of caspase-3 and bypasses fas-and TNFR1-dependent signaling. *European Journal of Biochemistry*; 266: 750-761.
- **Dudich I et al (1998):** Growth-regulative activity of human alpha-fetoprotein for different types of tumor and normal cells. *Tumor Biology*; 19: 30-40.

- **Dudich I et al (1999):** Isolation and structural and functional characterization of the two stable peptide fragments of human alpha-fetoprotein. *Biochemistry*; 38: 10406-10414.
- **Dugaiczyk, A., Law, S. W. & Dennison (1982):** *Proc. Natl. Acad. Sci. USA*; 79, 71-75.
- **El-aserg HB (2002):** hepatocellular carcinoma and hepatitis c in the United States. *Hepatology*; 36 (suppl 1):S74-83.
- **Elmén, Joacim et al (2008):** "LNA-Mediated Microrna Silencing In Non-Human Primates." *Nature* 452: 896-899.
- **El-Zanaty F (2009):** Egyptian Ministry of Health. El-Zanaty and Associates, and Macro International. Cairo. p 431, 2009. Egypt Demographic Health Survey: Final Report - June 2009. This study completed the first representative national sample of HCV antibody and HCV RNA. The final estimated prevalence of HCV antibody was 14.7%. Way A. Egypt Demographic and Health Survey.
- **Enomoto, Nobuyuki, Maekawa and Shinya (2010):** "HCV Genetic Elements Determining the Early Response to Peginterferon and Ribavirin Therapy". *Intervirology* 53 (1): 66.
- **Erica E. M. Moodie, Nitika Pant Pai and Marina B. Klein (2009):** Is Antiretroviral Therapy Causing Long-Term Liver Damage? A Comparative Analysis of HIV-Mono-Infected and HIV/Hepatitis C Co-Infected Cohorts. *PLoS ONE*; 4(2): e`4517. Doi: 10.1371/journal. Pone. 0004517.

- **Esteban C et al (1993):** Activation of an alpha-fetoprotein/receptor pathway in human normal and malignant peripheral blood mononuclear cells. *Leukemia*; 7(11): 1807-1816.
- **European Paediatric Hepatitis C Virus Network (Dis 2005):** A significant sex but not elective cesarean section effect on mother-to-child transmission of hepatitis C virus infection. *J Infect*; 192:1872-9.
- **F Carrat, P Bedossa, F Lunel-Fabiani and others (2008):** Serum alpha-fetoprotein predicts virologic response to hepatitis C treatment in HIV coinfecting patients. *AIDS* 22: 1513-1515.
- **Fabio Piscaglia, Alessandro Cucchetti, Eleonora Terzi and Alice Gianstefani (2011):** Validation of noninvasive methods for the assessment of liver fibrosis in patients with recurrent hepatitis C after transplantation. *Liver Transplantation*; Volume 16, Issue 8, pages 1006–1007.
- **Falconer K, Sandberg JK, Reichard O and Alaeus A (2009):** "HCV/HIV Coinfection at a large HIV outpatient clinic in Sweden: Feasibility and results of hepatitis C treatment". *Scandinavian Journal of infectious diseases*; 41 (11-12): 881–5.
- **Festin SM et al (1999):** The recombinant third domain of human alpha-fetoprotein retains the antiestrogenic activity found in the full length molecule. *Biochimica Biophysica Acta*; 1427(2): 307-314.
- **Fissell RB, Bragg-Gresham JL, Woods JD et al (2004):** Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. *Kidney Int*; 65(6):2335.

- **Franciscus and Alan (2010):** Hepatitis C treatments in current development, HCV Advocate; 1-22.
- **Francois M, Dubois F, Brand D et al (1993):** Prevalence and significance of hepatitis C virus (HCV) viremia in HCV antibody-positive subjects from various populations. J Clin Microbiol; 31(5):1189.
- **Frank C et al (2000):** The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet; 355, 887-891.
- **Frank C, Mohamed MK, Strickland GT et al (2000):** The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet; 355:887-91.
- **Frank C, Mohamed MK, Strickland GT et al (March 2000):** "The Role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt". Lancet; 355 (9207): 887–91.
- **Fung J, Lai CL, Hung I et al (September 2008):** "Chronic hepatitis C virus genotype 6 infection response to pegylated interferon and ribavirin". The Journal of infectious diseases; 198 (6): 808–12.
- **Gaeta GB, Stornaiuolo G, Precone DF, Lobello S, Chiaramonte M, Stroffolini T, Colucci G and Rizzetto M (2003):** Epidemiological and clinical burden of chronic hepatitis C virus infection. A multicenter Italian study. J Hepatol; 39(6):1036-41.
- **Ge D, Fellay J, Thompson AJ et al (September 2009):** "Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance". Nature 461 (7262): 399–401.

- **Ghany MG, Strader DB, Thomas DL and Seeff LBI (2009):** Diagnosis, management, and treatment of hepatitis C: an update. *Hepatology*; 49:1335–1374.
- **Gillespie JR and Uversky VN (2000):** Structure and function of alpha-fetoprotein: a biophysical overview. *Biochimica Biophysica Acta*; 1480(1-2): 41-56.
- **Goldstein D and Laszlo J (Sep 1988):** "The role of interferon in cancer therapy: a current perspective". *CA: a cancer journal for clinicians* 38 (5): 258–77.
- **Goldstein N S, Blue D E, Hankin R, Hunter S, Bayati N, Silverman A L and Gordon S C (1999):** Serum alpha-fetoprotein levels in patients with chronic hepatitis C. Relationships with serum alanine aminotransferase values, histologic activity index, and hepatocyte MIB-1 scores. Department of Anatomic Pathology, William Beaumont Hospital, Royal Oak, MI 48073, *American journal of clinical pathology*; 111(6):811-6. USA.
- **Goldstein, Arthur I, Farrell and Richard c (March 1978):** Physiologic Jaundice of the Newborn: Relation to Maternal Serum and Amniotic Fluid Alpha-Fetoprotein. *Obstetrics & Gynecology*; 51(3):315-317.
- **Graves (2002):** Alpha-fetoprotein is a major plasma protein produced by the yolk sac 65(5):915-22 .
- **Gray PW and Goeddel DV (1982):** "Structure of the human immune interferon gene". *Nature* 298 (5877): 859–63.

- **Hadziyannis SJ, Sette H, Morgan TR et al (2004):** Peginterferon alfa 2-a and ribovirin combination therapy in chronic hepatitis C: randomized study of the effect of treatment in duration and ribavirin dose. *Ann Inter Med*; 140: 346-355.
- **Hahn JA (2007):** "Sex, drugs and hepatitis C virus". *J Infect Dis*; 195 (11): 1556–9.
- **Haley RW and Fischer RP (2001):** Commercial tattooing as a potentially important source of hepatitis C infection. *Clinical epidemiology of 626 consecutive patients unaware of their hepatitis C serologic status. Medicine (Baltimore)*; 80(2):134.
- **Halfon P, Munteanu M and Poynard T (September 2008):** "FibroTest-ActiTest as a non-invasive marker of liver fibrosis". *Gastroentérologie Clinique et Biologique*; 32 (6 Suppl 1): 22–39.
- **Haller, O, Kochs G and Weber F (2007):** "Interferon, Mx, and viral countermeasures". *Cytokine Growth Factor Rev.* 18 (5-6): 425–33.
- **Hamel S et al (1987):** Phenotype and function of bone marrow-derived T and non-T cells activated in vitro by alpha-fetoprotein. In: Mizejewski GJ and Jacobson HI (editors) *Biological Activities of Alpha-fetoprotein*. Boca Raton, FL: CRC Press; Vol 1: pp167-177.
- **Hanaa M El-Karakasy, Nehal M El-Koofy, Ghada M Anwar, Fatma M El-Mougy, Ahmed El-Hennawy and Mona E Fahmy (2011):** Predictors of chronic liver diseases and advanced fibrosis in morbidly obese patients. *Volume: 17; Issue: 1; Page: 40-46.*
- **Harper ME and Dugaiczky A (July 1983):** "Linkage of the evolutionarily-related serum albumin and alpha-fetoprotein genes

within q11-22 of human chromosome 4". American journal of human genetics; 35 (4): 565–72.

- **Hepburn MJ and Lawitz EJ (2004):** Seroprevalence of hepatitis C and associated risk factors among an urban population in Haiti. BMC Gastroenterol. 14; 4: 31.
- **Herrine SK (2002):** Approach to the patients with chronic hepatitis c virus infection. Ann Intern Med; 136:747-57.
- **Hideyuki Nomura, Yoichiro Kashiwagi, Ryouko Hirano, Hironori Tanimoto, Nobuo Tsutsumi, Masashi Higashi and Hiromi Ishibashi (2007):** Efficacy of low dose long-term interferon monotherapy in aged patients with chronic hepatitis C genotype 1 and its relation to alpha-fetoprotein: Hepatology Research (Volume 37, Issue 7, pages 490–497.
- **Hinrichsen H, Benhamou Y, Wedemeyer H et al (November 2004):** "Short-term antiviral efficacy of BILN 2061, A Hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients". Gastroenterology; 127 (5): 1347–55.
- **Hirai H (1982):** Alpha fetoprotein in Biochemical markers for cancers. New York: Marcel Dekker; 23-59.
- **Hiromi Kataoka (February 2001):**Department of Internal Medicine, Nagoya City University Medical School Nagoya, 467-8601, Japan15; Volume 20, Number 7, Pages 869-873
- **Hoofnagle JH (2002):** course and outcome of Hepatitis C. Hepatology; 36 (5 suppl.1):S21-S29.

- **Hooper DC and Evans RG (1989):** Anti-proliferative action of murine alpha-fetoprotein on activated T-lymphocytes. *Journal of Reproductive Immunology*; 16 (1): 83-96.
- **Hoskin DW et al (1985):** In vitro activation of bone marrow-derived T-and non-T-cell subsets by alpha-fetoprotein. *Cellular Immunology* 96(1): 163-174.
- **Hostetter M and Haddow J (1980):** hereditary tyrosinemia. *Pediatric Research*; Vol. 14 No. 4, II pp. 52.
- **Houghton M (November 2009):** "The Long and Winding Road leading to the identification of the hepatitis C virus". *Journal of Hepatology*; 51 (5): 939–48.
- **Houghton m, Weiner a, Han J et al (1991):** Molecular biology of the hepatitis C virus: implications for diagnosis development and control of viral disease. *Hepatology*; 14:381-388.
- **Houghton, M., Q.-L. Choo, and G. Kuo (November 1988):** NANBV diagnostics and vaccines. European patent no; EP-0-3 18-216-A1.
- **Hung CH, Lee CM, Lu SN, Wang JH, Hu TH, Tung HD, Chen CH, Chen WJ and Changchien CS (2006):** Long-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. *J Viral Hepat*;13(6):409-14
- **Inaba K, Suzuki S, Sakaguchi T and Chen JS (2007):** Double primary liver cancer (intrahepatic cholangiocarcinoma and

hepatocellular carcinoma) in a patient with hepatitis C virus-related cirrhosis. *J Hepatobiliary Pancreat Surg*; 14:204–209.

- **Integrated serum screening for Down syndrome in primary obstetric practice (Dec 2005):** *Prenat Diagn*; 25(12):1162-7.
- **Irony-Tur-Sinai M et al (2006):** Amelioration of autoimmune neuroinflammation by recombinant human alpha-fetoprotein. *Experimental Neurology* 198(1): 136-144.
- **Jacobson HI et al (1990):** Inhibition of estrogen-dependent breast cancer growth by a reaction product of alpha-fetoprotein and estradiol. *Cancer Research* 50: 415-420.
- **Jaeckel E, Cornberg M, Wedemeyer H, Santantonio T, Mayer J, Zankel M, Pastore G, Dietrich M, Trautwein C and Manns MP (November 2001):** "Treatment of acute hepatitis C with interferon alfa-2b". *New England Journal of Medicine* 345 (20): 1452–1457.
- **Jain SK, Pemberton PW and Smith A et al. (2002):** Oxidative stress in chronic hepatitis C: not just a feature of late stage disease. *J Hepatol*; 36: 805-811.
- **Jamall IS, Yusuf S, Azhar M and Jamall S (November 2008):** "Is pegylated interferon superior to interferon, with ribavarin, in chronic hepatitis C genotypes 2/3?" *World J. Gastroenterol.* 14 (43): 6627–31.
- **Jassam N, Jones CM, Briscoe T and Horner JH (2006):** "The hook effect: a need for constant vigilance." *Ann. Clin. Biochem.* 43 (Pt 4): 314–7.
- **Jean-Claude Trinchet, Nathalie Ganne-Carrié, Pierre Nahon, Gisèle N'kontchou and Michel Beaugrand (2007):** Hepatocellular

carcinoma in patients with hepatitis C virus-related chronic liver disease ISSN 1007-9327 CN 14-1219/R World J Gastroenterol 2007 May 7; 13(17): 2455-2460.

- **Jin-no K, Tanimizu M, Hyodo I et al (1997):** Plasma level of basic fibroblast growth factor increases with progression of chronic liver disease. J Gastroenterol; 32(1):119-21.
- **Johnson (2001):** Clinical Liver Dis. 5:145-59.
- **Johnson RJ, Gretch DR, Yamabe H et al (February 1993):** Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. The New England Journal of Medicine 328 (7): 465–70.
- **Journal of Gastroenterology and Hepatology., Tsung-Ming Chen, Pi-Teh Huang, Ming-Hung Tsai, Lien-Fu Lin, Chung-Cheng Liu, Ka-Sic Ho, Chuan-Pau Siauw, Po-Liang Chao and Jai-Nien Tung (2007):** Volume 22, Issue 5, pages 669–675.
- **Journal of hepatology (10/2005):** Serum alpha-fetoprotein levels in patients with advanced hepatitis C; 43(3):434-41.
- **Jun Hayashi, Yasuhiro Kishihara, Kumiko Ueno, Kouzaburo Yamaji, Yasunobu Kawakami, Norihiro Furusyo, Yasunori Sawayama and Seizaburo Kashiwagi (1998):** Age-related response to Interferon Alfa treatment in women vs men with chronic hepatitis C Virus Infection. Arch intern med; VOL, 158:177-181.
- **K Deterding, N Gruner and J Wiegand (2009):** Early versus delayed treatment of acute hepatitis C the German HEP-NET Acute HCV-III study - a randomized controlled trial. 44th Annual Meeting

of the European Association for the Study of the Liver. Copenhagen, Denmark; 22-26.

- **K. Luo, Z. Liu and P. Karayiannis (2010):** Effect of antiviral treatment on alfa-fetoprotein levels in HBV-related cirrhotic patients: early detection of hepatocellular carcinoma. *Journal of Viral Hepatitis*; Volume 17, Issue 7, pages 511–517.
- **K. Sanefuji, H. Kayashima, and H. Kayashima (2009):** “Characterization of hepatocellular carcinoma developed after achieving sustained virological response to interferon therapy for hepatitis C,” *Journal of Surgical Oncology*, vol. 99, no. 1, pp. 32–37, 2009.
- **Kamal SM (May 2008):** "Acute Hepatitis C: A Systematic Review". *The American Journal of Gastroenterology* 103 (5): 1283–97; Quiz 1298.
- **Kamel M, Ghaffar Y, Wasef, M, Wright M, Clark L and Miller (1992):** High HCV prevalence in Egyptian Blood donors. *Lancet*. 340 (8816): p.427.
- **Kano T, Kojima T, Takahashi T and Muto Y (1987):** Serum thyroid hormone levels in patients with fulminant hepatitis: usefulness of rT3 and the rT3/T3 ratio as prognostic indices. *Gastroenterol Jpn*; 22:344 –53.
- **Karamova ER et al (1998):** Conformational variants of human alpha-fetoprotein. *Tumor Biology*; 19: 310-317.
- **Karki S, Ghimire P, Tiwari BR and Rajkarnikar M (2008):** Seroprevalence of anti HCV antibodies among blood donors.

Kathmandu University Medical Journal; Vol. 6, No. 4, Issue 24, 491-496.

- **Karmochkine M, Carrat F, Dos Santos O, Cacoub P and Raguin G (November 2006):** "A case-control study of risk factors for Hepatitis C infection in patients with unexplained routes of infection". *Journal of viral hepatitis*; 13 (11): 775–82.
- **Kawaguchi T, Yoshida T, Harada M, Hisamoto T, Nagao Y et al (2004):** Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. *Am J Pathol*; 165: 1499-508.
- **Kazutaka Kurokohchi, Akihiro Deguchi, Tsutomu Masaki, Takashi Himoto, Hirohito Yoneyama, Mitsuyoshi Kobayashi, Tsuyoshi Maeta, Takaaki Kiuchi, Fumikazu Kohi, Hisaaki Miyoshi, Tomohiko Taminato and Shigeki Kuriyama (2007):** Successful treatment of hypovascular advanced hepatocellular carcinoma with lipiodol-targetting intervention radiology. *World J Gastroenterol*; 28; 13(32): 4398-4400.
- **Keel BA et al (1991):** Human alpha-fetoprotein purified from amniotic fluid enhances growth factor-mediated cell proliferation in vitro. *Molecular Reproduction and Development* 30(2): 112-118.
- **Keel BA et al (1991):** Synergistic action of purified alpha-fetoprotein and growth factors on the proliferation of porcine granulosa cells in monolayer culture. *Endocrinology*; 129: 217-225.
- **Keel BA et al (1992):** Purified human alpha fetoprotein inhibits growth factor-stimulated estradiol production by porcine granulosa cells in monolayer culture. *Endocrinology*; 130(6): 3715-3717.

- **Klein E (Feb 1993):** "Tumor Markers in Testis Cancer," Urologic Clinics of North America; Vol. 20 (1):200-212.
- **Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N et al (1981):** Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology; 1: 431–5.
- **Komatsuda A, Imai H, Wakui H, Hamai K, Ohtani H, Kodama T, Oyama Y, Miura AB and Nakamoto Y (1996):** Internal medicine Jornal; 35(7):529-533.
- **Koretz RL, Abbey H, Coleman E and Gitnick G (1993):** Non-A, non-B post-transfusion hepatitis: looking back in the second decade. Ann Intern Med 1993; 119: 110-5.
- **Kudo (2006):** Early detection and characterization of hepacyocellular carcinoma: value of imaging multistep human hepatocarcinosis. Intervirology 49 (1-2):64-69.
- **Kuhn R, Zhang W, Rossmann M, Pletnev S, Corver J, Lenches E et al (2002):** Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. 108:717–725.
- **Kuo G, Choo QL, Alter HJ et al (April 1989):** An Assay for Circulating Antibodies to a Major Etiologic Virus of Human Non-A, Non-B Hepatitis. Science 244 (4902): 362–4.
- **L.ehmann F-G (1975):** Early detection of hepatoma prospective studyin liver cirrhosis using passive hemagglutination and the radioimmunoassay. Ann N Y Acad Sci; 259:196-210.

- **Lagging M, Langeland N, Pedersen C et al (August 2008):** "Weight-Adjusted Dosing Of Ribavirin And Importance Of Hepatitis C Virus RNA Below 1000 IU/ML By Day 7 In Short-Term Peginterferon Therapy For Chronic Genotype 2/3 Hepatitis C Virus Infection". *Hepatology*; 48 (2): 695.
- **Lagging M, Langeland N, Pedersen C et al (June 2008):** "Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection". *Hepatology*; 47 (6): 1837–45.
- **Lagging M, Romero AI, Westin J et al (December 2006):** IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. *Hepatology*; 44 (6): 1617–25.
- **Lagging M, Wejstål R, Uhnöo I et al (2009):** Treatment of Hepatitis C Virus Infection: Updated Swedish Consensus Recommendations. *Scandinavian Journal of Infectious Diseases*; 41 (6-7): 389–402.
- **Lamarre D, Anderson PC, Bailey M et al (November 2003):** "An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus". *Nature*; 426 (6963): 186–9.
- **Lamarre D., Anderson P.C., Bailey M., Beaulieu P., Bolger G., Bonneau P et al (2003):** An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. *Nature*; 426:186–189.
- **Larson AM, Polson J, Fontana RJ, Davern TJ, Lalani E, Hynan LS et al (2005):** Acetaminophen-induced acute liver failure:

results of a United States multicenter, prospective study. *Hepatology*; 42: 1364-1372.

- **László Kalabay, Elemér Nemesánszky, Antal Csepregi, Mária Pusztay, Károly Dávid, Gábor Horváth, Ervin Ibrányi, László Telegdy, Alajos Pár, Adrienn Bíró, Béla Fekete, Judith Gervain, Margit Horányi, Pál Ribiczey, Mihály Csöndes, Mónika Kleiber, Szilvia Walentin, Zoltán Prohászka and George Füst (2004) :** Paradoxical alteration of acute phase protein levels in patients with chronic hepatitis C treated with IFN α 2b. *Int. Immunol*; 16(1): 51-54 doi:10.1093/intimm/dxh024.
- **Leal JA et al (1980):** Human alpha-fetoprotein enhances epidermal growth factor proliferation activity upon porcine granulosa cells in monolayer culture. *Endocrinology* 126: 669-671.
- **Leal JA et al (1991):** Human mammary tumor cell proliferation: primary role of platelet-derived growth factor and possible synergism with human alpha-fetoprotein. *Steroids* 56(5): 247-251.
- **Leutscher PD, Lagging M, Buhl MR et al (August 2010):** "Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C". *Hepatology* 52 (2): 430–5.
- **Leutscher PD, Lagging M, Buhl MR et al (August 2010):** "Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C". *Hepatology*; 52 (2): 430–5.
- **Li M et al (2002):** Enhancement of proliferation of HeLa cells by the alpha-fetoprotein. 34(6): 769-774.

- **Li M et al (2005):** Alpha-fetoprotein triggers hepatoma cells escaping from immune surveillance through altering the expression of Fas/FasL and tumor necrosis factor related apoptosis-inducing ligand and its receptor of lymphocytes and liver cancer cells. *World Journal of Gastroenterology*; 11(17): 2564-2569.
- **Li M et al (2005):** Effects of alpha fetoprotein on escape of Bel 7402 cells from attack of lymphocytes. *BMC Cancer*; 5: 96.
- **Li M et al (2009):** Alpha fetoprotein is a novel protein-binding partner for caspase-3 and blocks the apoptotic signaling pathway in human hepatoma cells. *International Journal of Cancer*; 124(12): 2845-2854.
- **Lin CY, Ding HJ, Lin T, Lin CC, Kuo TH and Kao CH (2010):** Positive correlation between serum liver enzyme levels and standard uptake values of liver on FDG-PET. *Clin Imaging*; 34(2):109-12.
- **Liu Y (2005):** professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. *Annu Rev Immunol*; 23: 275–306.
- **Liu Y et al (2006):** Hierarchy of alpha fetoprotein (AFP)-specific T cell responses in subjects with AFP-positive hepatocellular cancer. *Journal of Immunology*; 177(1): 712-721.
- **Lock G, Dirscherl M, Obermeier F et al (September 2006):** Hepatitis C - contamination of toothbrushes: *J. Viral Hepat*; 13 (9): 571–3.

- **Lok AS and Lai C-L (1989):** Alpha-Fetoprotein monitoring in Chinese patients with chronic hepatitis B virus infection: role in the early detection of hepatocellular carcinoma. *Hepatology*; 9:110-5.
- **Lu CY et al (1984):** Alpha-fetoprotein inhibits macrophage expression of Ia antigens. *Journal of Immunology*; 132(4): 1722-1727.
- **M. Karmochkine, F Carrat, O Dos Santos and others (November 2006):** A case-control study of risk factors for hepatitis C infection in patients with unexplained routes of infection. *Journal of Viral Hepatitis*; 13(11): 775-782.
- **Males S, Gad RR, Esmat G, Abobakr H, Anwar M, Rekacewicz C et al (2007):** Serum alpha-foetoprotein level predicts treatment outcome in chronic hepatitis C. *Antivir Ther*; 12:797-803.
- **Manns MP, Foster GR, Rockstroh JK, Zeuzem S, Zoulim F and Houghton M (2007):** "The Way Forward In HCV Treatment-Finding The Right Path". *Nat Rev Drug Discov* 6; (12): 991–1000.
- **Marcel Beld, Roel Sentjens, Sjoerd Rebers, Christine Weegink, Jan Weel, Cees Sol, and René Boom (2001):** Performance of the New Bayer VERSANT HCV RNA 3.0 Assay for quantitation of Hepatitis C Virus RNA in Plasma and Serum: Conversion to International Units and Comparison with the Roche COBAS Amplicor HCV Monitor, Version 2.0, Assay. *Journal of Clinical Microbiology*; p. 788-793, Vol. 40, No. 30095-1137.
- **Mark S. Sulkowski M.D, David L. Thomas, Shruti H. Mehta , Richard E. Chaisson and Richard D. Moore(2003):** Article first published online: 30 DEC DOI: 10.1053/jhep.2002.30319.

- **Martin-Walter Welker , Christoph Welsch , Aline Meyer, Iris Antes, Mario Albrecht, Nicole Forestier,Bernd Kronenberger, Thomas Lengauer, Albrecht Piiper, Stefan Zeuzem and Christoph Sarrazin (2010):** Dimerization of the hepatitis C virus nonstructural protein Protein Science. Volume 19, Issue 7, pages 1327–1336.
- **Masakuni Tateyama, Hiroshi Yatsuhashi, Naota Taura, Yasuhide Motoyoshi, Shinya Nagaoka, Kenji Yanagi, Seigo Abiru, Koji Yano, Atsumasa Komori and Kiyoshi Migita et al (Sunday, August 15, 2010):** Alpha-fetoprotein above normal levels as a risk factor for the development of hepatocellular carcinoma in patients infected with hepatitis C virus . Journal of Gastroenterology; 293-535.
- **Mast EE (2004):** "Mother-to-infant hepatitis C virus transmission and breastfeeding". Advances in Experimental Medicine and Biology; 554: 211–6. PMID 15384578.
- **Matilde Sánchez, Juan Berenguer, Pilar Miralles, Federico Alvarez, Juan Carlos Lopez, Jaime Cosin, Catalán Pilar, Margarita Ramçrez, Isabel Gutierrez, and Emilio Alvarez (2006):** Liver Biopsy Findings for HIV-Infected Patients with Chronic Hepatitis C and Persistently Normal Levels of Alanine Aminotransferase. Oxford Journal. Clinical Infectious Diseases; Volume43, Issue5 .Pp. 640-644.
- **Matsumori A, Ohashi N, Nishio R, Kakio T, Hara M, Furukawa Y, Ono K, Shioi T, Hasegawa K and Sasayama S (1997):** Apical hypertrophic cardiomyopathy and hepatitis C virus infection. Jpn Circ J; 63(6):433-8. PubMed PMID: 10406581.

- **Maynard M, Pradat P, Bailly F et al (March 2006):** Amantadine triple therapy for non-responder hepatitis C patients. Clues for controversies. *Journal of hepatology*; 44 (3): 484–90.
- **Mc Caffrey AP, Meuse L, Karimi M, Contag CH and Kay MA (August 2003):** A potent and specific morpholino antisense inhibitor of hepatitis C translation. *Hepatology*; 38 (2): 503–8.
- **Mc govern BH, Wurcel A, Kim AY et al (June 2006):** Acute Hepatitis C virus infection in incarcerated injection drug users. *Clinical Infectious Diseases*; 42 (12): 1663–70.
- **Mc Hutchison JG, Gordon SC, Schiff ER et al (1998):** Interferon alfa-2b alone or in combination -with ribavirin as initial treatment for chronic hepatitis C. *New England Journal of Medicine*; 339(21):1485–1492.
- **Mele A, Pulsoni A, Bianco E, Musto P, Szklo A, Sanpaolo MG, Iannitto E, DeRenzo A, Martino B, Liso V, Andrizzi C, Pusterla S, Dore F, Maresca M, Rapicetta M, Marcucci F, Mandelli F and Franceschi S (Aug 2003).** Hepatitis C virus and B-cell non-Hodgkin lymphomas: an Italian multicenter case-control study. *Blood*. 1; 102(3):996-9
- **Meng-Hsuan Hsieh, Li-Po Lee, Ming-Yen Hsieh, Kun-Bow Tsai, Jee-Fu Huang, Nai-Jen Hou, Shinn-Chern Chen, Zu-Yau Lin, Ming-Yuh Hsieh, Liang-Yen Wang, Chia-Yen Dai¹, Wan-Long Chuang and Ming-Lung Yu (2007):** Hepatic Steatosis and Fibrosis in Chronic Hepatitis C in Taiwan. *Jpn. J. Infect. Dis*; 60 (6), 377-381.
- **Michael YL, Carlson NE, Bowen DJ, Ritenbaugh C. Rebuttal (2009):** "Confirmatory bias and the persistent influence of discredited

data in interpreting the stress-cancer links". *Health Psychol*; 30(3):375-6. PubMed PMID: 21553983.

- **Miller F and Abu-Raddad L (2010):** Evidence of intense ongoing endemic transmission of hepatitis C virus in Egypt. *Proc. Natl. Acad. Sci. USA*. Doi: 10.1073/pnas.1008877107.
- **Miller JC and Lee SI (2005):** Screening for Hepatocellular Cancer in Cirrhosis Patients. *Radiology Rounds*; 3 (1): 102-9.
- **Mitsui T, Iwano K, Masuko K et al (1992):** Hepatitis C virus infection in medical personnel after needlestick accident. *Hepatology*; 16(5):1109.
- **Mizejewski GJ (1985):** New insights into AFP structure and function: potential biomedical applications. In: GJ Mizejewski and IH Porter. *Alpha-Fetoprotein and Congenital Disorders*; pp. 5-34.
- **Mizejewski GJ (1997):** Alpha-fetoprotein as a biologic response modifier: Relevance to domain and sub domain structure. *Proceedings of the Society of Experimental Biology and Medicine*; 215: 333-362.
- **Mizejewski GJ (1997):** Alpha-fetoprotein as a biologic response modifier: relevance to domain and subdomain structure. *Proc Soc Exp Biol Med*; 215:333–362.
- **Mizejewski GJ (2001):** Alpha-fetoprotein Structure and Function: Relevance to Isoforms, Epitopes, and Conformational Variants. *Experimental Biology and Medicine*; 226: 377-408.
- **Mizejewski GJ (2004):** Biological roles of alpha-fetoprotein during pregnancy and perinatal development. *Experimental Biology and Medicine*; 229(6): 439-463.

- **Mizejewski GJ (May 2001):** Alpha-fetoprotein structure and function: relevance to isoforms, epitopes, and conformational variants. *Experimental biology and medicine* (Maywood, N.J.); 226 (5): 377–408.
- **Mizejewski GJ and Butterstein G (2006):** Survey of functional activities of alpha-fetoprotein derived growth inhibitory peptides: review and prospects. *Current Protein and Peptide Science*; 7(1): 73–100.
- **Mohamadnejad M, Montazeri G, Fazlollahi A et al(2006):** Noninvasive markers of liver fibrosis and inflammation in chronic hepatitis C-virus related liver disease. *Am J Gastroenterol*; 101:2537-45.
- **Mohamed MK (2004):** Epidemiology of HCV in Egypt 2004. *The Afro-Arab Liver Journal*; vol 3, No2, pp 41-52.
- **Moiseeva O, Mallette FA, Mukhopadhyay UK, Moores A and Ferbeyre G (2006):** DNA damage signaling and p53-dependent senescence after prolonged beta-interferon stimulation. *Mol. Biol; Cell* 17 (4): 1583–92.
- **Moradpour D, Penin F and Rice C (2007):** Replication of hepatitis C virus. *Nat Rev Microbiol*; 5:453–463.
- **Mossman, K (2011):** *Viruses and Interferon: Current Research.* Caister Academic Press; ISBN 978-1-904455-81-3.
- **Moya A et al (2002):** Hepatocellular carcinoma: Can it be considered a controversial indication for liver transplantation in centers with high rates of hepatitis C? *Liver Transpl*, 8:1020-1027.

- **Murashima S, Tanaka M, Haramaki M, Yutani S, Nakashima Y, Harada K, Ide T, Kumashiro R and Sata M (2006):** decrease in AFP level related to administration of interferon in patients with chronic hepatitis C and a high level of AFP. *Dig Dis Sci*; 51(4):808-12.
- **Nagano Y and Kojima Y (October 1954):** "Pouvoir immunisant du virus vaccinal inactivé par des rayons ultraviolets" (in French). *C. R. Seances Soc. Biol. Fil*; 148 (19-20): 1700–2. PMID 14364998.
- **Nagata S, Taira H, Hall A et al (1980):** Synthesis in *E. coli* of a polypeptide with human leukocyte interferon activity. *Nature* 284 (5754): 316–20.
- **Nathan C et al (1993):** Albumin inhibits neutrophil spreading and hydrogen peroxide release by blocking the shedding of DC43 (sialophorin, leukosialin). *Journal of Cell Biology* 122: 243-256.
- **Naval J et al (1985):** Cell type-specific receptors for AFP in a mouse T-lymphoma cell line. *Proceedings of the National Academy of Sciences (USA)* 82: 3301-3304.
- **Navratil V, de Chassey B et al (2010):** Systems-level comparison of protein-protein interactions between viruses and the human type I interferon system network. *Journal of Proteome Research*; 9 (7): 3527–36.
- **Nayak NC and Mital I (1977):** The dynamics of alpha-fetoprotein and albumin synthesis in human and rat liver during normal ontogeny. *Am J Pathol. Feb*; 86(2):359-74.
- **New Robin J.R. Blatt (30 Aug, 1990):** Prenatal Tests, *England Journal of Medicine*. 9; 323-325.

- **Ngo Y, Munteanu M, Messous D et al (October 2006):** A prospective analysis of the prognostic value of biomarkers (Fibrotest) in patients with chronic hepatitis C. *Clinical Chemistry*; 52 (10): 1887–96.
- **NIH consensus statement on management of hepatitis C (2002):** NIH consensus and state-of-the-science statements 19 (3): 1–46.
- **Nouso K, Kobayashi Y, Nakamura S, Kobayashi S, Takayama H, Toshimori J, Kuwaki K, Hagihara H, Onishi H, Miyake Y, Ikeda F, Shiraha H, Takaki A, Iwasaki Y, Kobashi H and Yamamoto K (Mar 2011):** Prognostic importance of fucosylated alpha-fetoprotein in hepatocellular carcinoma patients with low alpha-fetoprotein. *Journal of Gastroenterology and Hepatology*; 122: 243-256.
- **Nunez EA (1994):** Biological role of alpha-fetoprotein in the endocrinological field: Data and hypotheses. *Tumor Biology*; 15: 63-72.
- **Oberti F, ValsesiaE, Pilette C et al (1997):** Noninvasive diagnosis of hepatic fibrosis or cirrhosis. *Gastroenterology*;113:1609-1616.
- **Ohguchi, S, Nakatsukasa, H, Higashi, T et al (1998):** Expression of a-fetoprotein and albumin in human hepatocellular carcinomas: limitations in the application of the genes for targeting human hepatocellular carcinoma in gene therapy. *Hepatology*; 27: 599-706.
- **Oka H, Saito A, Ito K et al (2001):** Multicenter prospective analysis of newly diagnosed hepatocellular carcinoma with respect to the percentage of Lens culinaris agglutinin-reactive α -fetoprotein. *J Gastroen Hepatol*; 16: 1378-1383.

- **O'Neill G et al (1982):** Regulation of human lymphocyte activation by alpha-fetoprotein. Evidence of selective suppression of Ia-associated T-cell proliferation in vitro. *Onco-developmental Biology and Medicine*; 3(2-3): 135-150.
- **Osenberg S (2001):** Recent advances in the molecular biology of hepatitis C virus. *J Mol Biol*; 313(3): 451-64.
- **Ozato K, Uno K and Iwakura Y (May 2007):** "Another road to interferon: Yasuichi Nagano's journey". *J. Interferon Cytokine Res*; 27(5): 349–52.
- **Paolicelli, D; Drenzo, V and Trojano M (14 September 2009):** "Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis" (Free full text). *Biologics: targets & therapy*; 3: 369–76.
- **Pascual M, Perrin L, Giostra E and Schifferli JA (August 1990):** "Hepatitis C virus in patients with cryoglobulinemia type II". *The Journal of Infectious Diseases*; 162 (2): 569–70. PMID 2115556.
- **Paul Elias (2004):** "Hepatitis Drug-Maker Complaints Reviewed", the Associated Press, 27 February 2004.
- **Peck AB et al (1978):** Cellular and genetic restrictions in the immunoregulatory activity of alpha-fetoprotein. I. Selective inhibition of anti-Ia-associated proliferative reactions. *Journal of Experimental Medicine*; 147(3): 667-683.
- **Peck AB et al (1978):** Cellular and genetic restrictions in the immunoregulatory activity of alpha-fetoprotein. II. Alpha-fetoprotein-

induced suppression of cytotoxic T lymphocyte development. *Journal of Experimental Medicine*; 148(2): 360-372.

- **Pereira BJ, Milford EL, Kirkman RL and Levey AS (1991):** Transmission of hepatitis C virus by organ transplantation. *N Engl J Med*; 325(7):454.
- **Peters NG and Terrault NA (2002):** Alcohol use and hepatitis C. *Hepatology*; (supp 1): s220-5.
- **Pham, T. N. Q., MacParland, S. A., Mulrooney, P. M., Cooksley, H., Naoumov & Michalak, T (2004):** Hepatitis C virus persistence after spontaneous or treatment-induced resolution of hepatitis C. *J Virol*; 78, 5867–5874.
- **Philip Johnson (20 JAN 2009):** Role of alpha-fetoprotein in the diagnosis and management of hepatocellular carcinoma. 10.1046/j.1440-1746.1999.01873.
- **Pomper GJ, Wu Y and Snyder EL (2003):** Risks of transfusion-transmitted infections. *Curr Opin Hematol* 2003; 10(6):412.
- **Powel Brown, M.D., Ph.D (November 24, 2009):** Is professor of medicine and cancer prevention and clinical cancer prevention department chairman at the University of Texas M. D. Anderson Cancer Center and an editorial board member of Cancer Prevention Research. Source: American Association for Cancer Research.
- **Poynard T, McHutchison J, Manns M, et al (2002):** Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. *Gastroenterology*. 122:1303-13.

- **Pradat P, Tillmann HL, Sauleda S, Braconier JH, Saracco G, Thursz M, Goldin R, Winkler R, Alberti A, Esteban JI, Hadziyannis S, Rizzetto M, Thomas H, Manns MP, Trepo C and HENCORE Group (2007):** Long-term follow-up of the hepatitis C HENCORE cohort: response to therapy and occurrence of liver-related complications. *J Viral Hepat*; 2007 Aug; 14(8):556-63
- **Pratt DS and Kaplan MM (2002):** Evaluation of abnormal liver-enzyme results in asymptomatic patients. *N Engle J Med*; 342(17): 1266-71.
- **Rachel B Fissell, Jennifer L Bragg-Gresham, John D Woods, Michel Jadoul, Brenda Gillespie, Sara A Hedderwick, Hugh C Rayner, Roger N Greenwood, Takashi Akiba and Eric W Young (2004):** Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: The DOPPS. *Kidney International*; 65, 2335–2342.
- **Rehermann B and Nascimbeni M (2005):** Immunology of hepatitis B virus and hepatitis C virus infection. *Nat Rev Immunol*; 5:215-229.
- **Reichard, Andersson J, Schwarcz R and Weiland 0(1991):** Ribavirin treatment for chronic Hepatitis C. *Lancet*; 337:1058-61.
- **Robert Thimme, Hans-Christian Spangenberg, Spangenberg and Hubert E. Blum (2002):** Bridge over troubled water: Protection against hepatitis C virus persistence?Article first *Hepatology*; Volume 36, Issue 6, pages 1537–1539.
- **Roberto Franceschini, Antonio Picciotto, Angelo Cataldi, Giovanni Corsini, Nicoletta Sinelli, Emanuela Bruno, Tommaso Barreca and Ermanno Rolandi (1998):** Effect of interferon therapy

on serum alpha-fetoprotein levels in patients with chronic hepatitis C virus infection. *Current Therapeutic Research*; Volume 59, Issue 4 , Pages 223-226.

- **Rodger AJ, Roberts S and Lanigan A et al (2000):** Assessment of long term outcomes of community acquired hepatitis C. *Hepatology*; 32:582-587.
- **Romero AI, Lagging M and Westin J et al (October 2006):** "Interferon (IFN)-Gamma-Inducible Protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus Infection". *The Journal of infectious diseases*; 194 (7): 895–903.
- **Ruiz JD, Molitor F and Plagenhoef JA (November 2002):** "Trends In Hepatitis C And HIV Infection Among Inmates Entering Prisons In California, 1994 Versus 1999". *AIDS*; 16 (16): 2236–8.
- **Ryan KJ, Ray CG et al (2004):** *Sherris Medical Microbiology* (4th Ed.). McGraw Hill. Pp. 551–2. ISBN 0838585299.
- **Saldanha J, Lelie N and Heath A (1999):** Establishment of the first international standard for nucleic acid amplification technology (NAT) assays for HCV RNA. "WHO" Collaborative Study. Group. 1999. *Vox Sang*. 76 (3):149-58.
- **San Román M, Lezama L, Rojas E, Colina R, García L, Carlos A, Khan B and Cristina J (2002):** Analysis of genetic heterogeneity of hepatitis C viruses in Central America reveals a novel genetic lineage. Brief report. *Arch Virol*. Nov; 147(11):2239-46.

- **Sarobe P, Lasarate J and Garcia N et al (2006):** Characterization of T-cell responses against immunodominant epitopes from hepatitis C virus E2 and NS4a proteins. *J Viral Hepatol*; 47-55.
- **Sato Y, Nakata K and Kato Y et al (1993):** Early recognition of hepatocellular carcinoma based on altered profiles of alpha-fetoprotein. *N Engl J Med*; 328:1802-1806.
- **Schiodt FV, Ostapowicz G and Murray N et al (2006 Dec):** Alpha-fetoprotein and prognosis in acute liver failure. *Liver Transpl*; 12(12):1776-81.
- **Scott JD, McMahon BJ and Bruden D et al (April 2006):** High rate of spontaneous negativity for hepatitis C virus RNA after establishment of chronic infection in Alaska Natives. *Clinical Infectious Diseases*; 42 (7): 945–52.
- **Semenkova L et al (2003):** Alpha-fetoprotein positively regulates cytochrome c-mediated caspase activation and apoptosome complex formation. *European Journal of Biochemistry*; 270 (21): 4388-4399.
- **Semenkova LN et al (1997):** Alpha-fetoprotein as a TNF-resistance factor for human hepatocarcinoma cell line HepG2. *Tumor Biology*; 18: 30-40.
- **Semenkova LN et al (1998):** Alpha-fetoprotein-induced apoptosis of human hepatoma cells. *Tumor Biology*; 19: 261-.
- **Shahin M and Raslan H (Dec 2006):** Comparative Study of Three Amniotic Fluid Markers in Premature Rupture of Membranes: Prolactin, Beta Subunit of Human Chorionic Gonadotropin, and Alpha-Fetoprotein. *Gynecol Obstet Invest*; 7: 63(4):195-199.

- **Sherris, John C, Ryan, Kenneth J and Ray C (2004):** Sherris medical microbiology: an introduction to infectious diseases. New York: McGraw-Hill. Chp 15 Principles of Laboratory Diagnosis; ISBN 0-8385-8529-9.

- **Shiffman ML, Diago M, Tran A, Pockros P, Reindollar R, Prati D, Rodríguez-Torres M, Lardelli P, Blotner S and Zeuzem S (May 2006):** Chronic hepatitis C in patients with persistently normal alanine transaminase levels. *Clinical gastroenterology and hepatology*; 4 (5): 645–52.

- **Shiffman ML, Suter F, Bacon BR et al (July 2007):** Peginterferon Alfa-2a and ribavirin for 16 Or 24 weeks in HCV genotype 2 or 3. *The New England Journal of medicine*; 357 (2): 124–34.

- **Shimizu A, Shiraki K, Ito T, Sugimoto K, Sakai T, Ohmori S, Murata K et al (2002):** Sequential fluctuation pattern of serum desgamma-carboxy prothrombin levels detected by high-sensitive electrochemiluminescence systems an early predictive marker for hepatocellular carcinoma in patients with cirrhosis. *Int JMol Med*; 9:245–50.

- **Shiratori Y, Ito Y, Yokosuka O, Imazeki F, Nakata R, Tanaka N et al (2005):** Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. *Ann Intern Med*; 142:105–14.

- **Shiro Murashima, Masatoshi Tanaka, Makoto Haramaki, Shigeru Yutani, Yutaka Nakashima, Kazunori Harada, Tatsuya Ide, Ryukichi Kumashiro and Michio Sata (2006):** Decrease in AFP Level Related to Administration of Interferon in Patients with

Chronic Hepatitis C and a High Level of AFP. Volume 51, Number 4, 808-812, DOI: 10.1007/s10620-006-3211-2.

- **Simmonds P, Bukh J, Combet C, Deléage G, Enomoto N, Feinstone S, Halfon P, Inchauspé G, Kuiken C, Maertens G, Mizokami M, Murphy D, Okamoto H, Pawlotsky J, Penin F, Sablon E, Shin-I T, Stuyver L, Thiel H, Viazov S, Weiner A and Widell A (2005):** Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. *Hepatology*; 42 (4): 962–73.
- **Smith CJP and Kelleher PC (1980):** Alpha-fetoprotein molecular heterogeneity: Physiologic correlation with normal growth, carcinogenesis, and tumor growth. *Biochimica Biophysica Acta*; 605: 1-32.
- **Stadler R et al (2006):** Long-term survival benefit after adjuvant treatment of cutaneous melanoma with dacarbazine and low dose natural interferon alpha: A controlled, randomised multicentre trial. *Acta Oncologica*; Volume 45, Issue 4, pages 389–399.
- **Stedman C (2002):** Herbal hepatotoxicity. *Semin Liver Dis*; 22:195-206.
- **Sterling RK, Lissen E, Clumeck N et al (2006):** Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. *Hepatology*; 43:1317-1325.
- **Steven K. Herrine and Victor J. Navarro (2006):** Antiviral therapy of HCV in the cirrhotic and transplant candidate. *Int J Med Sci*; 3:75-78

- **Strecker H.J., schnorr G. K. and seidel L (1988):** Solid phase"sandwich"- (2-site IRMA)-assays for CEA, AFP, HCG and TSH employing monoclonal antibody. *Jornal of analytical chemistry*; 330:343.
- **Sutton AJ, Hope VD, Mathei C et al (2008):** A comparison between the force of infection estimates for blood-borne viruses in injecting drug user populations across the European Union: a modelling study. *J Viral Hepat*; 2008; 15(11):809.
- **Suzuki Y et al (1992):** Isolation and characterization of a specific alpha-fetoprotein receptor on human monocytes. *Journal of Clinical Investigation*; 90: 1530-1536.
- **Tai WC, Hu TH, Wang JH, Hung CH, Lu SN, Changchien CS and Lee CM (2009):** Clinical implications of alpha-fetoprotein in chronic hepatitis C. *J Formos Med Assoc*; 108(3):210-8.
- **Tai WC, Hu TH, Wang JH, Hung CH, Lu SN, Changchien CS and Lee CM (Mar 2009):** Clinical implications of alpha-fetoprotein in chronic hepatitis C. *J Formos Med Assoc*; 108(3):210-8.
- **Takaoka A, Hayakawa S, Yanai H et al (2003):** Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. *Nature* 424 (6948): 516–23.
- **Thomas DL, Thio CL, Martin MP et al (October 2009):** Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. *Nature* 461 (7265): 798–801.

- **Thomas DL, Thio CL, Martin MP et al (October 2009):** Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. *Nature* 461(7265):798–801.
- **Ting-Kai Leung, Chi-Ming Lee, Li-Kuo Shen, Hsi-Chi Chen, Yu-Cheng Kuok and Jeng-Fong Chiou (2005):** Role of alpha-fetoprotein in severity of liver diseases. ISSN 1007-9327 CN 14-1219/R *World J Gastroenterol* 2005 March 21;11(11):1697-1699
- **Toder V et al (1983):** Immunoregulatory mechanisms in pregnancy. II. Further characterization of suppressor lymphocytes induced by alpha-fetoprotein in lymphoid cell cultures. *Journal of Clinical and Laboratory Immunology*; 11(3): 149-154.
- **Toder V et al (1983):** the effect of alpha-fetoprotein on the growth of placental cells in vitro. *Placenta*; 4: 79-86.
- **Tohme RA and Holmberg SD (June 2010):** Is Sexual Contact A Major Mode Of Hepatitis C Virus Transmission? *Hepatology* 52 (4).
- **Tomasi TB (1977):** Structure and function of alpha-fetoprotein. *Annual review of medicine*; 28: 453–65.
- **Tomasi TB (1977):** Structure and function of alpha-fetoprotein. *Annu .Rev Med.* 1977; 28:453-65. Review.
- **Torres JM et al (1989):** Expression of alpha-fetoprotein receptors by human T-lymphocytes during blastic transformation. *Molecular Immunology*; 26(9): 851-857.
- **Toukan A, Kimball K and Alpert E (1990):** Prognostic significance of alpha-fetoprotein in chronic viral hepatitis: results of a long-term follow-up study. *Gastroenterology*; 98:640.

- **Trojan J et al (1989):** Alpha-fetoprotein (AFP) in granulomatous inflammation of the mouse. *British Journal of Experimental Pathology* 70 (4): 469-478.
- **Tsamandas AC, Syrokosta I, Thomopoulos K, Zolota V, Dimitropoulou D, Liava A et al (2006):** Potential role of hepatic progenitor cells expression in cases of chronic hepatitis C and their relation to response to therapy: a clinicopathologic study. *Liver Int*; 26:817-826.
- **Tsung-Ming Chen, Pi-Teh Huang, Ming-Hung Tsai, Lien-Fu Lin, Chung-Cheng Liu, Ka-Sic Ho, Chuan-Pau Siau, Po-Liang Chao and Jai-Nien Tung (05/2007):** Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy *Journal of gastroenterology and hepatology*; 22(5):669-75.
- **Uriel J (1989):** The physiological role of alpha-fetoprotein in cell growth and differentiation. *Journal of Nuclear Medicine and Allied Sciences*; 33: 12-17.
- **Ursula Plöckinger, Denny Krüger, Alexandra Bergk, Viola Weich, Bertram Wiedenmann and Thomas Bergv (2007):** Hepatitis-C patients have reduced growth hormone (GH) secretion which improves during long-term therapy with pegylated interferon-alpha. *American Journal of Gastroenterology*; Volume 102, Issue: 12, Pages: 2724-2731.

- **Vakharia D and Mizejewski GJ (2000):** Human alpha-fetoprotein peptides bind estrogen receptor and estradiol and suppress breast cancer. *Breast Cancer Research and Treatment* 63: 41-52.
- **Vandelli C, Renzo F, Romanò L et al (May 2004):** "Lack of evidence of sexual transmission of hepatitis C among monogamous couples: results of a 10-years prospective follow-up study". *The American journal of gastroenterology*; 99 (5): 855–9.
- **Velázquez RF, Rodríguez M, Navascués CA, Linares A, Pérez R, Sotorríos NG, Martínez I and Rodrigo L (2003 Mar):** Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. *Hepatology*; 37(3): 520-7.
- **Vento S, Garofano T and Renzini C (1998):** Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. *N Engl J*; 338: 286–90.
- **Vescio MF, Longo B, Babudieri S et al (April 2008):** "Correlates of Hepatitis C Virus Seropositivity in Prison Inmates: A Meta-Analysis". *Journal of Epidemiology and Community Health*; 62 (4): 305–13.
- **Vetvicka V et al (1988):** Alpha-fetoprotein and phagocytosis in athymic nude mice. *Immunology Letters*; 19(2): 95-98.
- **Vilcek (2003):** Novel interferons. *Nature Immunology*, Volume 4, pages 8-9.
- **Villacampa MJ et al (1984):** Alpha-fetoprotein receptors in a human breast cancer cell line. *Biochemical Biophysical Research Communications*; 122: 1322-1327.

- **Voroteliak EA et al (1996):** Alpha-fetoprotein suppresses keratinocyte proliferation in vitro. *Izvestiia Akadmii Nauk. Seriia Biologicheskaja*; (1): 117-120.
- **Wakita T., Pietschmann T., Kato T., Date T., Miyamoto M., Zhao Z et al (2003):** Production of infectious hepatitis C virus in tissue culture from cloned viral genome. *Nat Med* x; 11:791–796.
- **Wang XW and Xie H (1998):** Stimulation of tumor cell growth by alpha-fetoprotein. *International Journal of Cancer*; 75: 596-599.
- **Wang XW and Xie H (1999):** Alpha-fetoprotein enhances the proliferation of human hepatoma cells in vitro. *Life Sciences* 64 (1): 17-23.
- **Wang XW and Xie H (1999):** Growth inhibition of human liver cancer cells by alpha-fetoprotein antisense strategy. *In vitro Cellular and Developmental Biology - Animal* 35: 118-119.
- **Watanabe H, Saito T, Shinzawa H et al (September 2003):** "Spontaneous Elimination of Serum Hepatitis C Virus (HCV) RNA in Chronic HCV Carriers: A Population-Based Cohort Study". *Journal of Medical Virology* 71 (1): 56–61.
- **Weissenbach J, Chernajovsky Y, Zeevi M et al (December 1980):** "Two interferon mRNAs in human fibroblasts: in vitro translation and *Escherichia coli* cloning studies". *Proc. Natl. Acad. Sci. U.S.A.* 77 (12): 7152–6.
- **Willson, L. Corey, D. Gretch, R. Willson, R. Carithers, M. Busch J. Hart and J. Han (1994):** Assessment of Hepatitis C Virus RNA Levels by Quantitative Competitive RNA polymerase chain reaction:

High-Titer Viremia Correlates with Advanced Stage of Disease *J Infect Dis.* 169(6): 1219-1225.

- **World J Gastroenterol (2010 June):** 28; 16(24): 3049–3055. Published online 2010 June 28. Doi: 10.3748/wjg.v16.i24.3049.
- **Wright TL (1993):** Etiology of fulminant hepatic failure: is another virus involved? *Gastroenterology* 1993; 104:640-3.
- **Yachida S, Fukushima N, Nakanishi Y, Akasu T, Kitamura H, Sakamoto M and Shimoda T (2003):** Alpha-fetoprotein-producing carcinoma of the colon: report of a case and review of the literature. *Dis Colon Rectum*; 46: 826-831.
- **Yakimenko EF et al (1998):** Epitope mapping of human alpha-fetoprotein. *Tumor Biology*; 19: 301-309.
- **Yamashita T et al (1994):** Evidence that alpha-fetoprotein suppresses the immunological function in transgenic mice. *Biochemical Biophysical Research Communications*; 201(3): 1154-1159.
- **Yasuji Arase, Kenji Ikeda, Fumitaka Suzuki, Yoshiyuki Suzuki, Masahiro Kobayashi, Norio Akuta, Tetsuya Hosaka, Hitomi Sezaki, Hiromi Yatsuji, Yusuke Kawamura, Mariko Kobayashi and Hiromitsu Kumada (2007):** Prolonged-interferon therapy reduces hepatocarcinogenesis in aged-patients with chronic hepatitis C. *Journal of Medical Virology*; Volume 79, Issue 8, pages 1095–1102.
- **Yasushi Tamura, Satoshi Yamagiwa, Yohei Aoki, So Kurita, Takeshi Suda, Shogo Ohkoshi, Minoru Nomoto and Yutaka Aoyagi (2009):** Serum alpha-fetoprotein levels during and after

interferon therapy and the development of hepatocellular carcinoma in patients with chronic hepatitis C. *Digestive Diseases and Sciences*; Volume: 54, Issue: 11, Pages: 2530-2537.

- **Yeung LT, King SM and Roberts EA (2001):** Mother-to-infant transmission of hepatitis C virus. *Hepatology*; 34:223-9.
- **Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, Inoue O, Yano M, Tanaka M, Fujiyama S, Nishiguchi S, Kuroki T, Imazeki F, Yokosuka O, Kinoyama S, Yamada G and Omata M (1999):** Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. *Ann Intern Med*; 3;131(3):174-81.
- **Yuxiang Wei, Changmei Yang, Baojun Wei, Jie Huang, Lunan Wang, Shuang Meng, Rui Zhang and Jinming Li (2008):** RNase-Resistant Virus-Like Particles Containing Long Chimeric RNA Sequences Produced by Two-Plasmid Coexpression System *J Clin Microbiol*; 46(5): 1734–1740.
- **Zagon IS, Donahue RN, Rogosnitzky M and McLaughlin PJ (August 2008):** Imiquimod upregulates the opioid growth factor receptor to inhibit cell proliferation independent of immune function. *Exp. Biol. Med.* (Maywood) 233 (8): 968–79.
- **Zarski JP, Bohn B, Bastie A et al (1998):** characteristics of patients with dual infection by hepatitis B and C viruses. *J Hepatol*; 28 (1): 27-33.

- **Zhang H, Hanecak R, Brown-Driver V et al (February 1999):** "Antisense oligonucleotide inhibition of hepatitis C virus (HCV) gene expression in livers of mice infected with an HCV-vaccinia virus recombinant". *Antimicrobial agents and chemotherapy* 43 (2): 347–53.
- **Zignego AL, Ferri C, Pileri SA, Caini P and Bianchi FB (January 2007):** Extrahepatic manifestations of Hepatitis C Virus infection: a general overview and guidelines for a clinical approach. *Digestive and Liver Disease*; 39 (1): 2–17.
- **Zignego AL, Ferri C, Pileri SA, Caini P and Bianchi FB (January 2007):** Extrahepatic manifestations of hepatitis C virus infection: A general overview and guidelines for a clinical approach. *Digestive and liver disease* 39; (1): 2–17.
- **Zucker K, Cirocco R, Roth D, Olson L, Burke GW, Nery J, Esquenazi V and Miller J (1994):** Depletion of hepatitis C virus from procured kidneys using pulsatile perfusion preservation. *Transplantation*; 1994; 57: 832-840.